allowing Altria to continue selling its products without major regulatory changes, at least in the near term. Around the same time, the Food and Drug Administration authorized 20 Zyn nicotine ...

Board of Directors (Board) named in our 2025 Proxy Statement; ratified the selection of PricewaterhouseCoopers LLP as our ...

further eroding Altria’s shares. Beyond consumer behavior, it faces mounting regulatory pressures. The U.S. Food and Drug Administration (FDA) has tightened restrictions on marketing practices.

Altria reported. Even though sales of vaping products the U.S. Food and Drug Administration has approved, like NJOY, face stiff competition from illegal devices, many of them imported from China ...